Global Innovative Contracting Review
H1 2024

With the arrival of Libmeldy priced at $4.25 million (wholesale price), we share insights from our U.S. payer network to explore the factors driving gene therapy prices up and down.

HEOR & ICER models often show that 1-time-curative medicines can be cost-effective, but that does not necessarily make them affordable.

We summarize the recent policy from the Department of Health for the Emirate of Abu Dhabi on establishing Managed Entry Agreements, which recognises the growing importance of these approaches for managing healthcare expenditure and clinical uncertainty of new technologies.

After a stagnant first 12 months of the IMF, we continue to see increased activity of new therapies entering this pathway; two treatments were added in May 2024, the first time we have seen multiple entrants in a single month.

There are multiple stages in the IMF pathway where Innovative Contracting can play a crucial role.

For the first time in history, two cell & gene therapies have been approved for the same indication by the FDA.

We explore how Innovative Contracting is being proactively used by BluebirdBio to help differentiate Lygenia from the competition, Casgevy.

See how a Pharmacy Benefit Manager is utilizing Innovative Contracting to overcome access barriers for GLP-1 receptor agonists following label expansion into chronic weight management.

It is no surprise there are budget impact concerns, with nearly 1 in 3 U.S. adults being categorized as overweight.

Nearly 5 years after the U.S. FDA approval of Trikafta, Cystic Fibrosis patients in South Africa have continued challenges in accessing this treatment.

In the absence of market registration, a new patient support program has been established to make Trikafta available, providing hope to some of the patients affected by the condition.